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Abstract In HL-60 cells signal transduction via sphingomyelin 
hydrolysis (sphingomyelin cycle) is induced by binding of tumor 
necrosis factor ¢x (TNFa) to cell surface TNFcz receptor. We 
found that IgG immunoglobufins activate sphingomyelin hydrol- 
ysis in plasma membrane of HL-60 cells, with kinetics similar to 
that of activation by TNFcx. Activation was induced by different 
IgG isotypes (most of which are irrelevant o known inducers of 
the sphingomyefin cycle) and also by Fcy fragments of IgG. The 
facts that inhibiting the binding of the antibodies to the cell 
surface by protein A prevents activation of sphingomyelin 
hydrolysis and that soluble TNF receptor of 55-kDa subtype 
(TBPss) inhibits activation, suggest hat the mechanism of IgG- 
induced sphingomyelin hydrolysis involves binding of IgGs 
through their Fc 7 domain to Fc7 surface receptors which mediate 
autocrine secretion of TNF~ The latter is responsible for 
inducing sphingomyelin hydrolysis. This study suggests that 
TBPss may be an effective inhibitor of the sphingomyelin cycle. 
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1. Introduction 
Recently it has become evident that the sphingomyelin 
(SPM) pathway plays a major role in signal transduction by 
regulating major stages in cell development such as cell divi- 
sion, differentiation, and apoptosis ([1,2] and references there- 
in). Ceramide, the lipid product of SPM hydrolysis, is formed 
due to the activation of neutral [3-5] and/or acidic [1] sphin- 
gomyelinases in many cell types by tumor necrosis factor c~ 
(TNFt~), interleukin-l~ (IL-I[3), vitamin D3, or nerve growth 
factor (NGF) [1,6]. The targets of the agents which initiate the 
signal are specific membrane receptors such as the 55-kDa 
TNFe~ receptor for TNFa  [7] or the low-affinity neurotropin 
receptor (p75 NTR) for NGF [6]. The ceramide formed can 
either be modified to other signaling products (ceramide-1- 
phosphate, sphingosine-l-phosphate, or sphingosine) or affect 
various functions directly by an as yet unknown mechanism. 
We found that IgG immunoglobulins, including anti-TNFc~ 
IgG, through their F~ domains, activate the SPM cycle, 
and that this process is inhibited by soluble 55-kDa TNF  
receptor (TBP55). 
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Abbreviations: anti-aLTX, purified rabbit anti-a latro-toxin; DCCM- 
1, defined cell culture medium; IL-I~, interleukin-ll3; MEMa, 
minimum essential medium alpha; NGF, nerve growth factor; PBS, 
phosphate-buffered saline; PC, phosphatidylcholine; SPM, sphingo- 
myelin; TBPs,~, TNF-binding protein of 55 kDa; TNFe~, tumor 
necrosis factor c~ 
This study was aimed at clarifying the mechanism by which 
IgG immunoglobulins activate the sphingomyelin cycle and 
identifying molecules which, through interaction with the ago- 
nist (TNF~), inhibit this cycle. 
2. Materials and methods 
The basic experimental system used was similar to that of Okazaki 
et al. [8] and Dressier et al. [9]. HL-60 cells were grown in suspension 
in MEMc~ medium (Biological Industries, Bet HaEmek, Israel), en- 
riched with vitamin solution and sodium pyruvate and containing 
10°/,7 fetal calf serum. The cells were grown at 37°C in 5% CO2 atmo- 
sphere in a 25-ml flask at a maximum concentration of 0.5 × 106 cells/ 
ml in the presence of 7.3×10 ~ dpm/ml [3H]choline (15 Ci/mmol, 
Amersham, Little Chalfont, Buckinghamshire, UK) for 48-72 h. 
Then the medium was removed and cells were washed (× 2) in phos- 
phate-buffered saline (PBS) (without Ca 2+ and Mg2+). The washed 
cells were incubated in 24-well plates in DCCM-1 medium (without 
fetal calf serum) (Biological Industries) at a concentration of 0.5 ×10 6 
cells/ml (final volume per well 1 ml) for the desired time (0-130 rain) 
at 37 ° in 5% CO2 atmosphere, in the presence of the agents described 
in the text, table, and figures. Incubation was terminated by cell lipid 
extraction [10]. The chloroforrnic enriched lower phase was washed 
x2 with synthetic upper phase (chloroform:methanol:water 6:94:96 
by volume) and the lower phase was evaporated under N2. After 
evaporation the samples were dissolved in chloroform:methanol 2:1
(v/v). Pure egg phosphatidylcholine (PC, Lipoid, Ludwigshafen, Ger- 
many) and egg SPM (Avanti Polar Lipids, Alabaster, AL, USA), 22 
~tg of each, were added to the washed lower phase of each sample as 
carrier. The chloroformic lower phase was evaporated to dryness, and 
the residue was dissolved in a small volume of chloroform:methanol 
2:1 (v/v) and applied to silica gel G (scored 10×20 cm, 250-1am TLC 
plates) (Analtech, Newark, DE, USA) [11]. The plates were developed 
in chloroform:methanol:water 65:35:5 (v/v). More than 90% of the 
radioactivity in the lipid was found in PC and SPM. For untreated 
cells at time 0 the labeling ratio [3H]PC/[3H]SPM was in the range of 
4:1. Neither TNF0t nor various IgG antibodies induced hydrolysis 
of PC in the timescale of our experiment; therefore the ratio of 
[3H]SPM to [3H]PC served as a more accurate measure of the level 
of SPM hydrolysis since it corrects for losses in extraction. Each 
experimental point was repeated in triplicate; standard eviation of 
each point was -<10%. Based on the trypan blue vital staining test, 15 
20°/,, of the HL-60 cells died during the 30-min incubation with 30 nM 
TNFc~, while no cell death occurred ue to incubation with the var- 
ious IgG antibodies used in this study. For more details ee legends to 
Table 1 and figures. 
3. Results and discussion 
3.1. Anti-TNFo~ IgG and other unrelated lgGs activate the 
SPM cycle 
It was previously reported that high concentrations of anti- 
TNFc~ antibodies inhibited the SPM cycle [12,13]. We tried to 
inhibit the TNF~-induced SPM hydrolysis activation in HL- 
60 cells using lower concentrations of human anti-TNFe~ IgG 
polyclonal antibodies. Rabbit anti-human TNFc~-neutralizing 
polyclonal antibodies (primarily IgG, Genzyme Cytokine Re- 
search Products, Cambridge, MA, USA) and human rTNF~ 
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Fig. 1. Inhibition of IgG-induced [aH]sphingomyelin hydrolysis in 
HL-60 by protein A. [aH]SPM labeled HL-60 cells were incubated 
with either 21 or 11 gg/ml rabbit anti-aLTX IgG antibodies or 
the same two concentrations of anti-c~LTX which were preincu- 
bated with 91 btg/ml of protein A for 45 min. For more details see 
Section 2. 
a 
Fig. 2. Involvement of IgG F~ domain in IgG-HL-60 cell interac- 
tion. a, b, c describe micrographs in which the fluorescence l vel of 
anti-rabbit FITC F(ab)2 is distributed on the surface of HL-60 cells 
(a,b,c in Table 1). For more details see text. 
(Chiron, Emmersville, CA, USA) were used in this experi- 
ment. To our surprise, not only did the polyclonal IgG anti- 
TNFc~ antibodies not inhibit the HL-60 SPM hydrolysis, they 
actually more than doubled it from 13+2.0% for 30 nM 
TNFc~ alone to 27 + 2.0% for 30 nM TNFc~ in the presence 
of 1:50 dilution of anti-TNFc~ antibodies. In order to assess 
the role of the anti-TNFc~ antibodies in the enhancement of 
SPM degradation, HL-60 cells were incubated with 50 btl 
(1:100 dilution) of the above anti-TNFc~ antibodies in the 
absence of TNF~. After 30 min incubation, 23.0 + 2.0% deg- 
radation of HL-60 [aH]SPM was obtained, suggesting that 
the anti-TNFc~ antibodies can act by themselves as inducers 
of the SPM cycle. This raises the question of specificity or, in 
particular, which domain of the IgG molecule is responsible 
for this activation. We addressed this by incubating 
[all]choline-labeled HL-60 cells with either (i) 11 ~g of pur- 
ified rabbit anti-c~ latro-toxin (anti-c~LTX) IgG antibodies 
(these polyclonal antibodies - a gift of Noam Emanuel, Lau- 
tenberg Center for General and Tumor Immunology, Hebrew 
University - Hadassah Medical School - were raised to neu- 
Table 1 
Involvement of IgG Fcy domain in IgG interaction with HL-60 cells 
Experimental system 
HL-60 Primary Secondary anti-rabbit Protein 4°C incubation 
cells antibodies FITC-F(ab)2 A (+azide) 
Results 
37°C incubation Binding Capping Internalization 
(-azide) (4°C+azide) (37°C -azide) (37°C -azide) 
+ - -  _ _ q- 
o r  . . . .  
+ - -  + - -  + 
+ + + - -  + 
+ + + - -  _ 
+ + + + + 
+ + + + - -  
q- _ _ _ 
- t -a  __  __  
+ + + +b 
_ c _ _ 
-}. _ _ _ 
~,h'~Micrographs a,b,c in Fig. 2. 
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Fig. 3. Effect of TNFa and IgG on the time-dependent levels of 
[3H]SPM in HL-60 cells. [3H]SPM-labeled HL-60 cells were incu- 
bated in the presence of either 30 nM TNF~z (D) or anti-etLTX IgG 
(0) (50 ~tg/well). Incubation was carried out as described in the text 
for the specified time. For more details ee Section 2. 
tralize spider poison and therefore are irrelevant o TNFc~ 
neutralization or binding) or (ii) 50 lag protein of a fraction 
of unspecific human immunoglobulins which is enriched with 
IgG (Octagam, Octapharma AG, Glarus, Switzerland). 
Both the specific rabbit anti-czLTX antibodies and the hu- 
man immunoglobulins activate the SPM cycle, reaching 
20.0+2.0% SPM degradation. Since the only common de- 
nominator of all these three antibody fractions is the Fc 7 
domain, we studied directly the involvement of this domain 
(i) by incubating HL-60 cells with purified unreduced 2-chain 
Fcq, fragment (Jackson Immuno Research, West Grove, PA, 
USA) and (ii) by studying the effect of protein A (Zymed, 
South San Francisco, CA, USA) on the SPM hydrolysis in- 
duced by IgG antibodies. The unreduced 2-chain Fcq, frag- 
ment activates the SPM cycle inducing 23.0 + 3.0% SPM hy- 
drolysis in a way similar to that of intact antibodies. More 
support for the primary involvement of the F~ domain of 
IgG molecules comes from the results (Fig. 1) which demon- 
strate that protein A, which binds with high affinity to the Fc 7 
domain of most IgGs other than subclass IgG3 [14], inhibits 
the IgG-induced SPM hydrolysis in a manner which is de- 
pendent on the ratio of protein A to IgG. 
3.2. Mechanism of IgG-induced activation of SPM cycle 
To study the mode of interaction of IgG antibodies with the 
HL-60 cells we incubated cells with 10 ~tg/ml anti-czLTX IgG 
antibodies in MEMcz medium containing 0.5% sodium azide. 
After 30 min at 4°C, FITC-labeled secondary F(ab)2 derived 
from goat anti-rabbit antibodies lacking the Fq  domain (Sig- 
ma, St. Louis, MO, USA) were added. The cells were incu- 
bated at 4°C for 30 min, washed × 2, and then transferred to 
azide-free medium at 37°C. For both temperatures (4°C and 
37°C) the distribution of the antibodies in the cells and on the 
cell surface was followed by fluorescence microscopy. The 
results are described in Table 1 and Fig. 2. The results in 
Table 1 clearly show that the primary antibodies bind to the 
cell surface at 4°C in the presence of azide (Fig. 2a), while 
incubation at 37°C in the absence of azide leads to capping 
and internalization (Fig. 2b). This binding is inhibited by pro- 
tein A (Fig. 2c). This experiment also demonstrates that the 
F(ab)2, which lack the F~ domain, do not activate the SPM 
cycle. 
In order to elucidate the involvement of TNFc~ in the IgG- 
induced [3H]SPM hydrolysis we first compared the kinetics of 
hydrolysis induced by TNFcz and anti-czLTX IgG. Fig. 3 
shows that there is a similarity in the kinetics between the 
TNFcx-induced SPM hydrolysis and antibody-induced hydrol- 
ysis. It is well established that the TNFc~-induced hydrolysis 
has a typical kinetic profile. The hydrolysis tarts immediately 
after contact of the cells with TNFa  and in HL-60 cells 
reaches a maximum at about 30-60 min post-contact with 
TNFcx, followed by a recovery phase and reaching the levels 
of before the interaction of the cells with TNFc¢ (or even 
higher values) of [3H]SPM at 90-120 min after initial contact 
with TNFc~ [5,9]. The profile of the kinetics of hydrolysis 
induced by anti-czLTX IgG was similar to that obtained 
with TNFc~, except that the level of maximum hydrolysis 
was higher (Fig. 3) for TNFc~-induced SPM hydrolysis. The 
involvement of TNFc~ in the process could not be investigated 
using anti-TNFc~ antibodies (see above). Therefore we looked 
for a monovalent agent that has TNFc~-binding properties 
similar to the membrane TNFc~ receptor which participates 
in the SPM cycle. TBP55, the stable, single-chain, single-site, 
55-kDa TNFc~-binding protein (a gift of Prof. D. Wallach, 
Weizmann Institute of Science, Rehovot, Israel) is such an 
agent. It inhibits TNFc~-induced SPM hydrolysis in a concen- 
tration-dependent manner. TBPsJTNFct in a molar ratio of 
3.3 (100 nM/30 nM) results in 16% inhibition of [3H]SPM 
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Fig. 4. TBPss inhibits IgG- and Fcy fragment-induced hydrolysis of 
[3H]SPM in [3H]SPM-labeled HL-60 cells. [3H]SPM-labeled HL-60 
cells (see text) were incubated for 45 rain at 37°C in DCCM-1 medi- 
um containing either 21 gg rabbit anti-aLTX IgG antibodies (see 
Fig. 1) or 50 gg Fc~ fragments either in the presence or absence of 
540 nM TBPss (30 gg/well) for 40 min at 37°C. For more details 
see Section 2. 
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Fig. 5. Scheme of proposed mechanism for IgG-induced sphingo- 
myelin hydrolysis in HL-60 cells. Dimerization (or oligomerization) 
of FcyR by Fq domain of IgG induces fast release of TNFo, which 
activates the sphingomyelin cycle in the autocrine and/or paracrine 
modes. 
hydrolysis, while in a molar ratio of 30 (900 nM/30 nM), 
inhibition is 47%. When the TBPss was added to the incuba- 
tion mixture containing HL-60 cells and anti-aLTX IgG anti- 
bodies or containing HL-60 cells and Fey fragments, hydro- 
lysis of SPM was either almost completely inhibited (for IgG) 
or reduced (Fey fragments) (Fig. 4). 
TBP5,s inhibition of IgG-induced SPM hydrolysis is greater 
than TBPss inhibition of SPM hydrolysis induced by 30 nM 
TNFa. This is explained by the high molar ratio of 1000: 1 
(TBPss/ TNFa) required to obtain complete neutralization of 
TNFo! [15,16] and the lower TNFcl concentration present in 
the IgG-induced SPM cycle than in the HL-60 cells incubated 
with 30 nM TNFa. These experiments suggest that TBPs5 can 
be used to study if a mechanism of inducing or inhibiting a 
process is mediated by secreted TNFa. For example, vitamin 
Da-induced activation of the SPM cycle in HL-60 cells [8] is 
also inhibited by TBPss, suggesting mediation by autocrine 
and/or paracrine secretion of TNFa (Glick and Barenholz, 
unpublished data). 
Studies on the interaction of the IgG antibodies (or Fey 
fragments) with HL-60 cells (Table 1) suggest that the primary 
event is the binding of the antibodies to the Fey receptor on 
the HL-60 cell surface, which leads to Fey receptor (FcyR) 
cross-linkage, the latter inducing autocrine and/or paracrine 
TNFcl secretion, which activates the SPM cycle (Fig. 5). The 
hydrolysis of SPM can be inhibited either by preventing bind- 
ing to cell membrane Fey receptors, as exemplified by protein 
D. Glick, Y BarenholzlFEBS Letters 394 (1996) 237-240 
A, or by neutralizing the secreted TNFa by its soluble recep- 
tor protein TBPss. 
It can be assumed that the cytokine antidotes were secreted 
as a response to elevated levels of the cytokines. Therefore, 
one may anticipate that in vivo the kinetics of TNFa secretion 
and the balance between TNFa and TBPs may control major 
events mediated by the SPM cycle, such as differentiation and 
apoptosis of white blood cells. This may explain some of the 
clinical effects observed during treatment with immunoglobu- 
lins [17]. 
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